Preventing SARS-CoV-2 infection by modulating viral host receptors, such as angiotensin-converting
enzyme 2 (ACE2) 1 , could represent a new chemoprophylactic approach for …

There is a rapidly expanding literature on the in vitro antiviral activity of drugs that may be
repurposed for therapy or chemoprophylaxis against severe acute respiratory syndrome‐…

Objectives AGILE is a Phase Ib/IIa platform for rapidly evaluating COVID-19 treatments. In
this trial (NCT04746183) we evaluated the safety and optimal dose of molnupiravir in …

Rationale: We examined whether increased rifampin doses could shorten standard therapy
for tuberculosis without increased toxicity. Objectives: To assess the differences across three …

Background: The importance of predicting human pharmacokinetics during compound
selection has been recognized in the pharmaceutical industry. To this end there are many …

Background Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) has been
declared a global pandemic and urgent treatment and prevention strategies are needed. …

Objectives The oxazolidinone linezolid is an effective component of drug-resistant TB treatment,
but its use is limited by toxicity and the optimum dose is uncertain. Current strategies are …

Objectives Favipiravir has discrepant activity against SARS-CoV-2 in vitro, concerns about
teratogenicity and pill burden, and an unknown optimal dose. This analysis used available …

Repurposing approved drugs may rapidly establish effective interventions during a public
health crisis. This has yielded immunomodulatory treatments for severe coronavirus disease …

Our aims were to address three fundamental questions relating to the symptoms of
community-acquired pneumonia (CAP): Do patients completely recover from pneumonia symptoms? …